U.S. Veterinary Vaccines Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2032

Key Insights

The U.S. Veterinary Vaccines Market size was valued at USD 4.12 USD Billion in 2023 and is projected to reach USD 6.40 USD Billion by 2032, exhibiting a CAGR of 6.5 % during the forecast period. The vaccine is a biological preparation, that provokes an immune response in an animal that would enable it to develop immunity for specific diseases. There are large and diverse numbers of vaccines available, for example, there are live attenuated, inactivated, recombinant, and DNA vaccines. The vaccines create a desirable situation where these elements can be manifested under safety, efficacy, and duration of protection. Applications of such an approach may include stopping contagious diseases (viruses, parasites, etc) in farm animals, pets, and wildlife, and making a safer environment for all of us. In the US we find an increasing interest of consumers in these new-generation vaccines, individualized vaccines, and vaccines against rapidly increasing pathogens. More importantly, the focus is on improving vaccine accessibility, affordability, and sustainability to meet various animal health challenges. The latter does not necessarily mean the end of the world. 

U.S. Veterinary Vaccines Trends

• Increasing adoption of pets
• Rising awareness about animal health
• Growing prevalence of animal diseases
• Technological advancements in vaccine development
• Government initiatives to promote animal health

Driving Forces: What's Propelling the U.S. Veterinary Vaccines Market

• Increased adoption of companion animals: The increasing number of pet owners in the U.S. is driving the demand for veterinary vaccines. Companion animals, such as dogs and cats, are more likely to be vaccinated than livestock due to their close contact with humans and other animals.
• Rising awareness of animal health: Pet owners are becoming more aware of the importance of animal health and the role of vaccines in preventing diseases. This awareness is being driven by media coverage of animal diseases, as well as educational campaigns by veterinarians and animal welfare organizations.
• Growing prevalence of animal diseases: The increasing prevalence of animal diseases, such as rabies, canine distemper, and feline leukemia, is also driving the demand for vaccines. These diseases can be spread through contact with infected animals or wildlife, or through contaminated food or water.

Challenges and Restraints in U.S. Veterinary Vaccines Market

• Cost of vaccines: The cost of vaccines can be a barrier to adoption, especially for low-income pet owners.
• Availability of vaccines: Some vaccines may not be available in all parts of the U.S. This can make it difficult for pet owners to get their pets vaccinated.
• Vaccine hesitancy: Some pet owners are hesitant to vaccinate their pets due to concerns about side effects or the perceived need for vaccines.

Emerging Trends in U.S. Veterinary Vaccines

• New vaccine technologies: New vaccine technologies, such as recombinant DNA vaccines and mRNA vaccines, are being developed to improve the safety and efficacy of vaccines.
• Personalized vaccines: Personalized vaccines are being developed to provide tailored protection against specific diseases.
• Veterinary telemedicine: Veterinary telemedicine is becoming more common, allowing pet owners to consult with veterinarians remotely. This can make it easier for pet owners to get their pets vaccinated.

Growth Catalysts in the U.S. Veterinary Vaccines Industry

• Government support for animal health: The U.S. government provides support for animal health through the Animal and Plant Health Inspection Service (APHIS). APHIS provides funding for vaccine research and development, as well as educational programs to promote animal health.
• Investment in veterinary research: Pharmaceutical companies are investing in veterinary research to develop new and improved vaccines. This investment is being driven by the growing demand for veterinary vaccines.

Market Segmentation: U.S. Veterinary Vaccines Analysis

The U.S. veterinary vaccines market is segmented by product, animal, route of administration, and distribution channel.

By Product

• Inactivated vaccines
• Live attenuated vaccines
• Recombinant vaccines
• Others (e.g., DNA vaccines, mRNA vaccines)

By Animal

• Companion animals (e.g., dogs, cats, horses)
• Livestock animals (e.g., cattle, swine, poultry)

By Route of Administration

• Oral
• Parenteral (e.g., intramuscular, subcutaneous)
• Others (e.g., transdermal, intranasal)

By Distribution Channel

• Veterinary hospitals
• Veterinary clinics
• Pharmacies & drug stores
• Others (e.g., online retailers, direct-to-consumer sales)

Leading Players in the U.S. Veterinary Vaccines Market

• Elanco (U.S.),
• HIPRA (Spain),
• Boehringer Ingelheim International GmbH (Germany),
• Virbac (France),
• MSD Animal Health (U.S.),
• Zoetis (U.S),
• Ceva (France),
• NEOGEN CORPORATION (U.S.),
• Hester Biosciences Limited (India)

Significant Developments in U.S. Veterinary Vaccines Sector

• February 2023: Mazen Animal Health received a patent from the U.S. Patent and Trademark Office (USPTO) for its maize-based vaccines against porcine epidemic diarrhea virus (PEDV).
• September 2022: MSD Animal Health launched Nobivac Intra-Trac Oral BbPi, the first and only oral vaccine against canine parainfluenza virus in the U.S.
• March 2022: Ceva launched a sow vaccine to prevent neonatal diarrhea. It is unique as it consists of 7 antigens and has increased its product portfolio.

Comprehensive Coverage U.S. Veterinary Vaccines Market Report

The U.S. veterinary vaccines market report provides a comprehensive analysis of the market, including:

• Market size and growth projections
• Key market trends and drivers
• Challenges and restraints
• Competitive landscape
• Segmentation analysis
• Emerging trends
• Growth catalysts

Regional Insight

The U.S. veterinary vaccines market is primarily driven by the companion animal segment. The increasing adoption of pets in the U.S. is the key factor driving the growth of this segment. The livestock segment is also expected to grow at a steady pace, driven by the growing demand for meat and poultry products.

Pricing Analysis

The pricing of veterinary vaccines varies depending on the product, animal, and route of administration. Inactivated vaccines are generally less expensive than live attenuated vaccines. Recombinant vaccines are the most expensive type of vaccine.

Import And Export Analysis

The U.S. is a net exporter of veterinary vaccines. The major export markets for U.S. veterinary vaccines include Canada, Mexico, and the European Union. The U.S. also imports veterinary vaccines from other countries, such as China and India.

Patent/Trademark Analysis

The U.S. Patent and Trademark Office (USPTO) has granted several patents related to veterinary vaccines. These patents cover a wide range of topics, including new vaccine technologies, vaccine formulations, and methods of use.

Some of the most recent patents granted by the USPTO include:

• U.S. Patent No. 11,412,800: "Vaccine for preventing canine parainfluenza virus"
• U.S. Patent No. 11,357,462: "Recombinant vaccine for preventing porcine reproductive and respiratory syndrome virus"
• U.S. Patent No. 11,268,604: "Method for producing a vaccine against avian influenza virus"

These patents are a valuable asset for companies developing and manufacturing veterinary vaccines. They provide exclusive rights to the patented technology, which can give companies a competitive advantage in the market.